cropped color_logo_with_background.png

Search of Protein Biomarkers in Order to Achieve a Molecular Classification of Gliomas

Study Purpose

The aim is to classify high grade glioma by matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI MSI). In order to provide more specific informations for the diagnosis and the prognosis of high grade glioma.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Main

inclusion criteria:

  • - Patients with grade III or IV glioma newly diagnosed with histological evidence.
  • - Surgical indication.
  • - Tumor tissue available at biobank of Lille.
  • - Men and women aged ≥ 18 years.
  • - Informed Consent signed by the patient or his legal representative.
Main

exclusion criteria:

  • - Antecedents of other cancers except basal cell skin cancer or carcinoma in situ of the uterus cervix.
  • - Previous history of brain radiotherapy.
  • - Anti-tumor systemic treatments (chemotherapy or targeted therapy) prior to surgery of glioma.
  • - Genetic disease that may cause brain tumor, potentially radiation-induced tumor.
  • - History of degenerative neurological disease prior to diagnosis.
- contraindication to MRI

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT02473484
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University Hospital, Lille
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Emilie Le RHUN, MD
Principal Investigator Affiliation University Hospital, Lille
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Completed
Countries France
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Glioblastoma

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Le Rhun, Lille, France

Status

Address

Le Rhun

Lille, , 59000